Adi Gilboa-Geffen
Chief Technology Officer Eleven Therapeutics
Seminars
Wednesday 15th July 2026
Harnessing AI-Driven xRNA Platforms to Deliver Ultra-Long-Acting Metabolic “Checkpoints” & Permanent Weight Stability
4:30 pm
- Utilizing the xRNA™ platform and “combinatorial genetics” to identify and silence high-impact metabolic targets, providing a “once-to-twice-a-year” dosing convenience that eliminates the daily or weekly “jab fatigue” associated with current peptide therapies
- Matching the durability of genetic interventions with a programmable siRNA design to offer a potent maintenance alternative, potentially capturing a dominant share of the post-incretin “transition market” by 2030 as payers demand therapies that prevent the $100B+ biological “rebound effect”
- Optimizing the metabolic “hand-off” protocol by transitioning patients from acute GLP-1 induction to RNA-based physiological regulation, ensuring permanent appetite control and improved insulin sensitivity without the “peaks and troughs” or gastrointestinal side effects of chronic hormonal supplementation
